Zone registry · checked 15 October 2026
Approved cell therapies in Boao Lecheng and their registered prices
19 entries across six hospitals: which technology, for which diagnosis, in which form and at which price announced by the zone administration. These are the hospitals' public prices, not ours; no such procedure in the zone is offered below them.
Where the figures come from. Since March 2025 the administration of the Boao Lecheng pilot zone has been publishing approvals of cell technologies for clinical use in batches, together with each hospital's registered price per procedure. It is the only regime in mainland China where such technologies are used lawfully on a paid basis; since 1 May 2026, cell procedures outside such regimes are illegal.
How to read the table. The price is per unit — one injection, one session or one course, as the hospital announced it. Where a course consists of several administrations we also show the course total. The dollar conversion is approximate, at about ¥7.2 per $1.
Entries are grouped by hospital: an approval always has an address, and a technology on one line does not transfer to another hospital or another diagnosis.
Ruijin Hospital Hainan (瑞金医院海南医院)
Hainan branch of Shanghai's Ruijin Hospital, Shanghai Jiao Tong University — the zone's first batch of approvals.
- Umbilical-cord MSCs into the knee
Degenerative knee osteoarthritis. One intra-articular injection of allogeneic mesenchymal stem cells.
Batch 1 · 22 Mar 2025
¥36,000per injection≈ $5,000 - Autologous airway basal cells
Moderate-to-severe COPD. Cells collected at bronchoscopy, expanded in the laboratory and returned to the lungs.
Batch 1 · 22 Mar 2025
¥150,000per session≈ $20,800 - Autologous airway basal cells
Interstitial lung disease, bronchiectasis.
Batch 2 · 26 Apr 2025
¥150,000per course≈ $20,800 - Dendritic-cell vaccine
Epstein–Barr-virus-associated haematological malignancies. No genetic modification of the cells.
2025
¥126,000per session≈ $17,500 - RPE65 gene therapy
Inherited retinal dystrophy with an RPE65 mutation. The registry's only gene-therapy entry.
2025
¥480,000per eye≈ $66,700
West China Lecheng Hospital, Sichuan University (四川大学华西乐城医院)
Branch of West China Hospital, one of the largest university hospitals in China.
- Umbilical-cord MSCs, intravenous
Chronic heart failure with reduced ejection fraction (≤ 40 %, NYHA II–IV). One infusion a week, a course of three.
Batch 1 · 22 Mar 2025
¥60,000per infusion · course ¥180,000≈ $8,300 - MSCs for graft-versus-host disease
A complication after bone-marrow transplantation.
Batch 2 · 26 Apr 2025
¥80,000per session≈ $11,100 - Umbilical-cord MSCs for rheumatoid arthritis
Intravenous administration for an inadequate response to standard therapy.
Batch 4 · Nov 2025
¥50,000per session≈ $6,950 - Personalised dendritic-cell vaccine
Malignant solid and haematological tumours. A course of 6–7 sessions.
Batch 2 · 26 Apr 2025
¥150,000per session≈ $20,800 - Cell vaccine against Epstein–Barr virus
EBV-related precancerous conditions of the nasopharynx.
Batch 3 · 30 Aug 2025
¥16,000per session≈ $2,200 - Autologous NK cells
Adjuvant treatment of solid tumours. A course of 3–6 sessions at the physician's discretion.
Batch 5 · 22 Mar 2026
¥49,800per session≈ $6,900
Ciming Boao International Hospital (慈铭博鳌国际医院)
A private hospital in the zone with two approvals: type 2 diabetes and premature ovarian insufficiency. About the hospital →
- Umbilical-cord MSCs for type 2 diabetes
Inadequate glycaemic control on three or more drugs. Three infusions about 28 days apart, dosed by body weight. Permit 乐医药监〔2025〕113号.
Batch 4 · Nov 2025
from ¥58,000per infusion · course from ¥174,000≈ from $8,050 - Umbilical-cord MSCs for premature ovarian insufficiency
Targeted injection into the ovarian stroma by transvaginal puncture. Permit 乐医药监〔2025〕62号.
Batch 3 · 30 Aug 2025
¥80,000per procedure≈ $11,100
Shulan (Boao) Hospital (树兰（博鳌）医院)
The hospital group of academician Zheng Shusen; its specialty is hepatology.
- MSCs for pulmonary fibrosis
Menstrual-blood-derived mesenchymal cells, a course.
Batch 3 · 30 Aug 2025
¥140,000per course≈ $19,400 - MSCs for decompensated liver cirrhosis
A course of infusions for decompensation despite standard therapy.
Batch 5 · 22 Mar 2026
¥150,000per course≈ $20,800 - Autologous NK cells
Solid tumours; prevention of recurrence after radical treatment.
Batch 5 · 22 Mar 2026
¥70,000per session≈ $9,700 - Activated T lymphocytes
Prevention of recurrence after resection of liver cancer.
Batch 4 · 1 Nov 2025
¥100,000per session≈ $13,900
Boao Super Hospital (博鳌超级医院)
The zone's multi-specialty hospital, built to generate real-world clinical data on new technologies.
- Autologous dendritic cells
Immune-associated solid tumours: pancreatic, colorectal and others. The most expensive cellular entry in the registry.
Batch 5 · 22 Mar 2026
¥194,000per injection≈ $26,900
Yiling Hospital / Yiling Life Care Center (一龄医院)
A health and prevention centre; one dental entry in the registry.
- Dental-pulp MSCs for severe periodontitis
Regeneration of periodontal tissue, priced per tooth.
Batch 4 · Nov 2025
¥59,800per tooth≈ $8,300
What it means
Registry approval: what it gives you and what it does not
Four things worth understanding before you compare the numbers.
- Approval is a legal status, not proof
A permit from the zone administration means a hospital may lawfully use the technology in patients for the approved indication. It says nothing about the strength of the evidence: for most entries that evidence is early-phase.
- Tied to one hospital and one indication
Each line of the registry is a specific hospital, a specific diagnosis and a specific route of administration. The same technology at another hospital, or for another diagnosis, is not covered.
- The price covers the procedure only
Diagnostics, hospital stay beyond the procedure, accommodation, transfers and interpreting are not included. They are costed separately, and we send the estimate in writing before you book flights.
- The hospital's physician decides the indication
Being in the registry does not mean you qualify for it. Whether a technology is indicated for you is decided by the physician after an in-person work-up; we do not replace that decision.
Plainly
What is not in the registry
If you are offered a cell programme that is not on this list, it is not necessarily a scam — but it is a reason to ask questions. Our method pages carry a “Status and evidence” block for exactly that.
- Anti-age stem-cell infusions
Systemic MSC infusions “for rejuvenation” are absent from the zone's registry. Such programmes are offered as wellness, not as approved treatment.
- Exosomes and “immunomodulation”
Injectable exosomes and generic “immune support programmes” are not on the list. That is not a ban, but it is not an approval either: ask for the legal basis.
- Neurology and paediatric diagnoses
There is no cell therapy for stroke sequelae, multiple sclerosis, autism or cerebral palsy in the registry. Two large phase 3 trials in stroke showed no effect.
- What to ask if a method is not listed
The permit number, the hospital, the indication and the price per unit. A normal answer is a document. “Proprietary method” is a reason to end the conversation.
Our prices
How the registry relates to MedBridge pricing
Cell and immune therapies on our pricing page are listed at no less than the zone's registered prices: you pay the hospital directly against its invoice, we add no markup to medicine, and we cannot make it cheaper than the registry.
If you see “stem cells in China” well below these figures, it is most likely not these cells, not this hospital, or not the zone at all. Send us the offer you are comparing and we will go through it together with your records — free, and in writing.
Programme prices → · Stem cells abroad: countries, clinics, prices → · How to verify MedBridge →
Is anything in the registry right for you?
Send your reports and scans — Dr Yang will say whether the trip makes sense and what order of cost to expect, before you travel. No obligation.